Venoarterial extracorporeal membrane oxygenation for cardiac support in human immunodeficiency virus-positive patients: a case report and review of a multicentre registry.
Cardiogenic shock
Extracorporeal life support (ECLS)
Extracorporeal life support Organization (ELSO)
Extracorporeal membrane oxygenation (ECMO)
Human immunodeficiency virus (HIV)
Venoarterial
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
07 Apr 2023
07 Apr 2023
Historique:
received:
22
06
2022
accepted:
26
03
2023
medline:
11
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
epublish
Résumé
Human immunodeficiency virus (HIV) is associated with increased risk of heart failure via multiple mechanisms both in patients with and without access to highly active antiretroviral therapy (HAART). Limited information is available on outcomes among this population supported on Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO), a form of temporary mechanical circulatory support. We aimed to assess outcomes and complications among patients with HIV supported on VA ECMO reported to a multicentre registry and present a case report of a 32 year old male requiring VA ECMO for cardiogenic shock as a consequence of his untreated HIV and acquired immune deficiency syndrome (AIDS). A retrospective analysis of the Extracorporeal Life Support Organization (ELSO) registry data from 1989 to 2019 was performed in HIV patients supported on VA ECMO. 36 HIV positive patients were reported to the ELSO Database who received VA ECMO during the study period with known outcomes. 15 patients (41%) survived to discharge. No significant differences existed between survivors and non-survivors in demographic variables, duration of VA ECMO support or cardiac parameters. Inotrope and/or vasopressor requirement prior to or during VA ECMO support was associated with increased mortality. Survivors were more likely to develop circuit thrombosis. The patient presented was supported on VA ECMO for 14 days and was discharged from hospital day 85. A limited number of patients with HIV have been supported with VA ECMO and more data is required to ascertain the indications for ECMO in this population. HIV should not be considered an absolute contraindication to VA ECMO as they may have comparable outcomes to other patient groups requiring VA ECMO support.
Sections du résumé
BACKGROUND
BACKGROUND
Human immunodeficiency virus (HIV) is associated with increased risk of heart failure via multiple mechanisms both in patients with and without access to highly active antiretroviral therapy (HAART). Limited information is available on outcomes among this population supported on Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO), a form of temporary mechanical circulatory support.
METHODS
METHODS
We aimed to assess outcomes and complications among patients with HIV supported on VA ECMO reported to a multicentre registry and present a case report of a 32 year old male requiring VA ECMO for cardiogenic shock as a consequence of his untreated HIV and acquired immune deficiency syndrome (AIDS). A retrospective analysis of the Extracorporeal Life Support Organization (ELSO) registry data from 1989 to 2019 was performed in HIV patients supported on VA ECMO.
RESULTS
RESULTS
36 HIV positive patients were reported to the ELSO Database who received VA ECMO during the study period with known outcomes. 15 patients (41%) survived to discharge. No significant differences existed between survivors and non-survivors in demographic variables, duration of VA ECMO support or cardiac parameters. Inotrope and/or vasopressor requirement prior to or during VA ECMO support was associated with increased mortality. Survivors were more likely to develop circuit thrombosis. The patient presented was supported on VA ECMO for 14 days and was discharged from hospital day 85.
CONCLUSIONS
CONCLUSIONS
A limited number of patients with HIV have been supported with VA ECMO and more data is required to ascertain the indications for ECMO in this population. HIV should not be considered an absolute contraindication to VA ECMO as they may have comparable outcomes to other patient groups requiring VA ECMO support.
Identifiants
pubmed: 37029414
doi: 10.1186/s13019-023-02191-8
pii: 10.1186/s13019-023-02191-8
pmc: PMC10080512
doi:
Types de publication
Case Reports
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109Informations de copyright
© 2023. Crown.
Références
Perfusion. 2020 Nov;35(8):772-777
pubmed: 32141382
Ann Thorac Surg. 2001 Mar;71(3 Suppl):S77-81; discussion S82-5
pubmed: 11265871
ASAIO J. 2019 Sep/Oct;65(7):e69-e71
pubmed: 30893131
Perfusion. 2018 Sep;33(6):433-437
pubmed: 29528776
Thorac Cardiovasc Surg Rep. 2015 Dec;4(1):18-20
pubmed: 26693121
Intensive Care Med. 2016 Dec;42(12):1922-1934
pubmed: 27647331
Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):120-7
pubmed: 19104517
J Heart Lung Transplant. 2013 Jan;32(1):106-11
pubmed: 23260710
J Thorac Dis. 2015 Jul;7(7):E166-76
pubmed: 26380745
Thorac Cardiovasc Surg. 2005 Aug;53(4):252-4
pubmed: 16037875
Lancet. 2020 Aug 22;396(10250):545-552
pubmed: 32828186
J Heart Lung Transplant. 2014 Sep;33(9):924-30
pubmed: 24929646
Circulation. 2014 Apr 29;129(17):1781-9
pubmed: 24778120
Health Serv Res. 2005 Oct;40(5 Pt 2):1620-39
pubmed: 16178999
Crit Care Med. 2008 May;36(5):1404-11
pubmed: 18434909
J Am Coll Cardiol. 2017 Jan 3;69(1):73-82
pubmed: 28057253
Circulation. 2013 Apr 30;127(17):1767-74
pubmed: 23543004
J Am Coll Cardiol. 2017 Jan 3;69(1):83-91
pubmed: 28057254
AIDS. 2013 Mar 27;27(6):973-979
pubmed: 23698063
AIDS Patient Care STDS. 2008 Oct;22(10):771-8
pubmed: 18783326
Biomed Res Int. 2016;2016:8196560
pubmed: 26885518